NOTE: The disclosure forms for Dr. Brinton, Dr. Jacobson, and Dr. Miller were updated on January 3, 2019. Both the updated forms and the original forms are included here.



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inf								
Identifying Info	ormation							
1. Given Name (First Name) Christie	2. Surname (Last Name) Ballantyne	ı		3. Date 25-September-2018				
4. Are you the corresponding author?	☐ Yes ✓ No	Yes No Corresponding Author's Name Deepak L. Bhatt						
5. Manuscript Title Cardiovascular Risk Reduction with Icosapent Ethyl in Hypertriglyceridemia								
6. Manuscript Identifying Number (if yo	ou know it)							
Section 2. The Work Unde	r Consideration for Pub	lication						
Did you or your institution at any time any aspect of the submitted work (inclustatistical analysis, etc.)?  Are there any relevant conflicts of in Relevant finance.  Place a check in the appropriate box of compensation) with entities as declicking the "Add +" box. You should	tial activities outside the escribed in the instructions.	e submitted whether you had Use one line for	work.  we financial relator each entity; ac	ign, manuscript preparation, tionships (regardless of amo dd as many lines as you need	unt			
Are there any relevant conflicts of in	iterest? 🗸 Yes 🗌 No	)						
If yes, please fill out the appropriate	information below.							
Name of Entity	Grant? Personal N	Ion-Financial Support	Other? Com	ments				
AstraZeneca			Consu	tant				
Amarin	<b>✓</b>			Research support (paid to tion, not individual); consultant				
Amgen	<b>✓</b>			Research support (paid to tion, not individual); consultant				
Eli Lilly			Consu	tant				
Esperion	<b>/</b>			Research support (paid to tion, not individual); consultant				
Matinas BioPharma	<b>√</b>		Consu	tant				



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Merck		<b>✓</b>			Consultant	
Novartis	<b>✓</b>	$\checkmark$			Grant/Research support (paid to institution, not individual); consultant	
Regeneron	$\checkmark$	<b>✓</b>			Grant/Research support (paid to institution, not individual); consultant	
Sanofi-Synthelabo	$\checkmark$	<b>✓</b>			Grant/Research support (paid to institution, not individual); consultant	
National Institutes of Health	<b>✓</b>				Grant/Research support (paid to institution, not individual)	
American Heart Association	<b>✓</b>				Grant/Research support (paid to institution, not individual)	
American Diabetes Association	<b>✓</b>				Grant/Research support (paid to institution, not individual)	
Boehringer Ingelheim		<b>✓</b>			Consultant	
Novo Nordisk		<b>✓</b>			Consultant	
Akcea	<b>✓</b>	<b>✓</b>			Grant/Research support (paid to institution, not individual); consultant	
Denka Seiken		<b>✓</b>			Consultant	
Gilead		<b>✓</b>		П	Consultant	
Section 4. Intellectual Property Patents & Copyrights  Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No  Section 5. Relationships not covered above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/ci						
At the time of manuscript acceptance, jo On occasion, journals may ask authors to						



#### Section 6.

#### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Ballantyne reports personal fees from AstraZeneca, grants and personal fees from Amarin, grants and personal fees from Amgen, personal fees from Eli Lilly, grants and personal fees from Esperion, personal fees from Matinas BioPharma, personal fees from Merck, grants and personal fees from Novartis, grants and personal fees from Regeneron, grants and personal fees from Sanofi-Synthelabo, grants from National Institutes of Health, grants from American Heart Association, grants from American Diabetes Association, personal fees from Boehringer Ingelheim, personal fees from Novo Nordisk, grants and personal fees from Akcea, personal fees from Denka Seiken, personal fees from Gilead, outside the submitted work;

#### **Evaluation and Feedback**

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation				
Identifying Inform	ation				
Given Name (First Name)  Deepak	2. Surname (Last Na Bhatt	ime)		3. Date 22-October-2018	
4. Are you the corresponding author?	✓ Yes No				
5. Manuscript Title Cardiovascular Risk Reduction with Icosa	apent Ethyl in Hype	rtriglyceridemia			
6. Manuscript Identifying Number (if you known 18-12792	ow it)				
Section 2. The Work Under Co	onsideration for F	Publication			
Did you or your institution <b>at any time</b> receivany aspect of the submitted work (including statistical analysis, etc.)?					tc.) for
Are there any relevant conflicts of intere	st? ✓ Yes	No			
If yes, please fill out the appropriate info Excess rows can be removed by pressing		ou have more thar	one entity pres	ss the "ADD" button to add a	row.
Name of Institution/Company	Grant? Personal Fees?	Non-Financial Support?	Other? Com	nments	
Amarin	<b>V</b>		Wome Chair a	rch Funding to Brigham and en's Hospital for my role as and International Principal igator for the REDUCE-IT trial	
Section 3. Relevant financial a	activities outside	the submitted	work.		
Place a check in the appropriate boxes ir of compensation) with entities as describle clicking the "Add +" box. You should rep	bed in the instructio	ons. Use one line fo	or each entity; a	dd as many lines as you need	d by
Are there any relevant conflicts of intere	st? ✓ Yes	No			
If yes, please fill out the appropriate info	rmation below.				
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Com	nments	
Amarin	<b>✓</b>		Resear and PI	rch Funding; REDUCE-IT Chair I	



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
AstraZeneca	<b>✓</b>				Research Funding; SAVOR-TIMI 53 co- PI; THEMIS co-PI
Bristol-Myers Squibb	✓				Research Funding; PI
Eisai	<b>✓</b>				Research Funding; PI
Ethicon	<b>✓</b>				Research Funding; PI
Medtronic	<b>✓</b>				Research Funding; SYMPLICITY HTN-3 co-PI
sanofi aventis	<b>✓</b>				Research funding; ODYSSEY Executive Steering Committee; SCORED and SOLOIST Chair
The Medicines Company	<b>✓</b>				Research Funding; co-PI and co-Chair of CHAMPION PLATFORM, CHAMPION PCI, and CHAMPION PHOENIX
FlowCo				<b>✓</b>	Unfunded research collaboration
PLx Pharma				✓	Unfunded research collaboration
akeda				✓	Unfunded research collaboration
Duke Clinical Research Institute		<b>✓</b>			Data Monitoring Committees; Clinical Trial Steering Committees
Mayo Clinic		$\checkmark$			Data Monitoring Committee
Population Health Research Institute		<b>✓</b>			Data Monitoring Committees; Operations Committee, Publications Committee, USA co-National Leader, and Steering Committee for a trial funded by Bayer (COMPASS)
American College of Cardiology		<b>V</b>	<b>✓</b>		Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, Accreditation Committee; Trustee; Chair, ACTION Registry Steering Committee. Non-financial support is travel reimbursement.
Belvoir Publications		<b>✓</b>			Editor in Chief, Harvard Heart Letter
Slack Publications		<b>✓</b>			Chief Medical Editor, Cardiology Today's Intervention
WebMD		<b>√</b>			CME Steering Committees
Elsevier		<b>✓</b>			Advisory Board, Elsevier Practice Update Cardiology
Medscape Cardiology				✓	Advisory Board
Regado Biosciences				✓	Advisory Board



Boston VA Research Institute				<b>✓</b>	Board of Directors
Society of Cardiovascular Patient Care		<b>✓</b>	<b>✓</b>		Board of Directors; Secretary/ Treasurer. Non-financial support is travel reimbursement.
American Heart Association			<b>✓</b>		Chair, American Heart Association Quality Oversight Committee. Non- financial support is travel reimbursement.
HMP Global		<b>✓</b>			Editor in Chief, Journal of Invasive Cardiology
Roche	<b>✓</b>				Research Funding; PI
Harvard Clinical Research Institute (now Baim Institute for Clinical Research)		<b>✓</b>			Executive Steering Committee for trial funded by Boehringer Ingelheim (RE-DUAL PCI); Data Monitoring Committee Chair for a trial funded by St. Jude, now Abbott (PORTICO)
Clinical Cardiology				$\checkmark$	Deputy Editor
Journal of the American College of Cardiology		<b>✓</b>			Guest Editor; Associate Editor
VA				<b>√</b>	Chair, VA Cardiovascular Assessment, Reporting and Tracking System (CART) Program, Research and Publications Committee
Pfizer	<b>✓</b>				Research Funding; steering committee
Forest Laboratories/AstraZeneca	<b>✓</b>				Research Funding; Clinical Events Committee Chair for ASCENT COPD
Ischemix	<b>✓</b>				Research Funding; PI
St. Jude Medical (now Abbott)				<b>√</b>	Site Co-investigator
Biotronik				<b>√</b>	Site Co-investigator
Cardax				<b>✓</b>	Advisory Board
Boston Scientific				<b>√</b>	Site Co-investigator
Amgen	<b>✓</b>				Research Funding; GOULD steering committee
Lilly	<b>✓</b>				Research Funding; steering committee
Chiesi	<b>✓</b>				Research Funding; co-PI and co-Chair of CHAMPION PHOENIX
Ironwood	<b>✓</b>				Research Funding
Cleveland Clinic		<b>✓</b>			Data Monitoring Committee
Mount Sinai School of Medicine		<b>✓</b>			Data Monitoring Committee for the ENVISAGE trial, funded by Daiichi Sankvo



Merck			<b>✓</b>	Unfunded research collaboration
Abbott	<b>✓</b>			Research Funding; XIENCE ST DAPT Executive Committee
Regeneron	<b>✓</b>			Research Funding; ODYSSEY Executive Steering Committee
Svelte			<b>✓</b>	Site Co-investigator
PhaseBio	<b>√</b>			Research Funding
ldorsia	<b>✓</b>			Research Funding
Synaptic	<b>√</b>			Research Funding
TobeSoft		<b>✓</b>		Board of Directors
Boehringer Ingelheim		<b>✓</b>	<b>✓</b>	Executive Steering Committee for trial funded by Boehringer Ingelheim (RE-DUAL PCI) with payments from Harvard Clinical Research Institute (now Baim Institute for Clinical Research); editorial support services limited to collation of coauthor comments and formatting
Bayer		<b>✓</b>		Operations Committee, Publications Committee, USA co-National Leader, and Steering Committee for a trial funded by Bayer (COMPASS), with payments from Population Health Research Institute
Novo Nordisk			<b>✓</b>	Unfunded research collaboration; editorial support services limited to collation of coauthor comments and formatting



Cartinu 5	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Bhatt reports grants from Amarin, during the conduct of the study; grants from Amarin, grants from AstraZeneca, grants from Bristol-Myers Squibb, grants from Eisai, grants from Ethicon, grants from Medtronic, grants from sanofi aventis, grants from The Medicines Company, other from FlowCo, other from PLx Pharma, other from Takeda, personal fees from Duke Clinical Research Institute, personal fees from Mayo Clinic, personal fees from Population Health Research Institute, personal fees and non-financial support from American College of Cardiology, personal fees from Belvoir Publications, personal fees from Slack Publications, personal fees from WebMD, personal fees from Elsevier, other from Medscape Cardiology, other from Regado Biosciences, other from Boston VA Research Institute, personal fees and non-financial support from Society of Cardiovascular Patient Care, non-financial support from American Heart Association, personal fees from HMP Global, grants from Roche, personal fees from Harvard Clinical Research Institute (now Baim Institute for Clinical Research), other from Clinical Cardiology, personal fees from Journal of the American College of Cardiology, other from VA, grants from Pfizer, grants from Forest Laboratories/AstraZeneca, grants from Ischemix, other from St. Jude Medical (now Abbott), other from Biotronik, other from Cardax, other from Boston Scientific, grants from Amgen, grants from Lilly, grants from Chiesi, grants from Ironwood, personal fees from Cleveland Clinic, personal fees from Mount Sinai School of Medicine, other from Merck, grants from Abbott, grants from Regeneron, other from Svelte, grants from PhaseBio, grants from Idorsia, grants from Synaptic, personal fees from TobeSoft, personal fees and other from Boehringer Ingelheim, personal fees from Bayer, other from Novo Nordisk, outside the submitted work; .

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	mation		
- Identifying illion	nation		
Given Name (First Name)  Eliot	2. Surname (Last Name) Brinton		3. Date 03-December-2018
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Auth Deepak L. Bhatt, N	
5. Manuscript Title Cardiovascular Risk Reduction with Icc	osapent Ethyl in Patients wi	th Elevated Triglycer	rides
6. Manuscript Identifying Number (if you k	know it)		
Section 2. The Work Under C	Consideration for Public	cation	
Did you or your institution <b>at any time</b> recany aspect of the submitted work (includin statistical analysis, etc.)?  Are there any relevant conflicts of interesting the state of the stat	ng but not limited to grants, da		nent, commercial, private foundation, etc.) for study design, manuscript preparation,
· ·	formation below. If you hav	ve more than one en	tity press the "ADD" button to add a row.
Name of Institution/Company	Grant'	n-Financial Support?	Comments
Amarin			Consulting honoraria
Section 3. Relevant financia	l activities outside the	submitted work.	
	ribed in the instructions. Useport relationships that we rest?	se one line for each e	ncial relationships (regardless of amount entity; add as many lines as you need by ne 36 months prior to publication.
Name of Entity	Grant	n-Financial Support	Comments
Amarin			Speaking and consulting honoraria
AstraZeneca			Speaking and consulting honoraria
Akcea			Speaking and consulting honoraria



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Arisaph		<b>√</b>			Consulting honoraria	
Kowa		<b>✓</b>			Speaking and consulting honoraria	
Amgen		<b>✓</b>			Speaking and consulting honoraria	
Kastle		<b>✓</b>			Speaking and consulting honoraria	
Merck		<b>✓</b>			Speaking and consulting honoraria	
Regeneron		<b>✓</b>			Speaking and consulting honoraria	
Sanofi		<b>✓</b>			Speaking and consulting honoraria	
Denka-Seiken		<b>✓</b>			Consulting honoraria	
Esperion		<b>✓</b>			Consulting honoraria	
Precision Biosciences		<b>✓</b>			Consulting honoraria	
PTS Diagnostics		<b>✓</b>			Consulting honoraria	
Medicure		$\checkmark$			Consulting honoraria	
Boehringer		<b>✓</b>			Speaking honoraria	
Janssen		<b>✓</b>			Speaking honoraria	
Kaneka		<b>✓</b>			Speaking honoraria	
Novo Nordisk		<b>✓</b>			Speaking honoraria	
Section 4.  Intellectual Property Patents & Copyrights  Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No						
Section 5. Relationships not c						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/cond						
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					· ·	



#### Section 6.

#### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Brinton reports personal fees from Amarin, during the conduct of the study; personal fees from Amarin, personal fees from AstraZeneca, personal fees from Akcea, personal fees from Arisaph, personal fees from Kowa, personal fees from Amgen, personal fees from Kastle, personal fees from Merck, personal fees from Regeneron, personal fees from Sanofi, personal fees from Denka-Seiken, personal fees from Esperion, personal fees from Precision Biosciences, personal fees from PTS Diagnostics, personal fees from Medicure, personal fees from Boehringer, personal fees from Janssen, personal fees from Kaneka, personal fees from Novo Nordisk, outside the submitted work.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation							
1. Given Name (First Name) Eliot	2. Surname (Last N Brinton	ame)	3. Date 25-September-2018					
4. Are you the corresponding author?	Yes ✓ No	·	ling Author's Name Bhatt, MD MPH					
5. Manuscript Title Cardiovascular Risk Reduction with Icos	apent Ethyl in Patie	ents with Elevated T	riglycerides					
6. Manuscript Identifying Number (if you kn	ow it)							
Section 2. The Work Under Co	onsideration for	Publication						
Did you or your institution <b>at any time</b> receive	ve payment or servic	es from a third party (	government, commercial, private foundation, etc.) for board, study design, manuscript preparation,					
Are there any relevant conflicts of intere	st? ✓ Yes	No						
If yes, please fill out the appropriate info		ou have more than	one entity press the "ADD" button to add a row.					
Excess rows can be removed by pressing	Excess rows can be removed by pressing the "X" button.							
Name of Institution/Company	Grant? Persona	Non-Financial Support?	Other? Comments					
Amarin			Consulting honoraria					
Section 3. Relevant financial a	activities outsid	e the submitted v	work.					
of compensation) with entities as descril	bed in the instructi	ons. Use one line fo	ve financial relationships (regardless of amount or each entity; add as many lines as you need by uring the 36 months prior to publication.					
Are there any relevant conflicts of intere	st? 🗸 Yes	No						
If yes, please fill out the appropriate info	rmation below.							
Name of Entity	Grant? Persona	Non-Financial Support?	Other? Comments					
Amarin			Speaking and consulting honoraria					
AstraZeneca			Speaking and consulting honoraria					
Akcea			Speaking and consulting honoraria					



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments			
Arisaph		<b>✓</b>			Consulting honoraria			
Kowa		<b>✓</b>			Consulting honoraria			
Denke-Seiken		<b>✓</b>			Consulting honoraria			
Medicure		<b>✓</b>			Consulting honoraria			
Section 4.  Intellectual Property Patents & Copyrights  Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo								
Section 5. Relationships not o	overed	above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?								
Yes, the following relationships/cond	litions/cir	cumstance	s are present (exp	olain belo	ow):			
✓ No other relationships/conditions/cir	cumstan	ces that pro	esent a potential	conflict o	finterest			
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.								
Section 6. Disclosure Stateme	nt							
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.								
Dr. Brinton reports personal fees from Amarin, during the conduct of the study; personal fees from Amarin, personal fees from AstraZeneca, personal fees from Akcea, personal fees from Arisaph, personal fees from Kowa, personal fees from Denke-Seiken, personal fees from Medicure, outside the submitted work.								



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Doyle 1



Section 1. Identifying Inform	ation							
Given Name (First Name) Ralph	Surname (Last Name)     Doyle		3. Date 25-September-2018					
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author Deepak L. Bhatt, M						
5. Manuscript Title Cardiovascular Risk Reduction with Icosapent Ethyl in Hypertriglyceridemia								
6. Manuscript Identifying Number (if you kn 18-12792	ow it)	_						
Section 2. The Work Under Co	onsideration for Publi	cation						
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No								
Section 3. Relevant financial a	activities outside the	submitted work.						
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes No  If yes, please fill out the appropriate information below.								
Name of Entity	Grant? Personal Fees? S	n-Financial other?	Comments					
Amarin Pharma Inc			Employee and stock shareholder of Amarin (sponsor)					
Section 4. Intellectual Proper	ty Patents & Copyri	ghts						
Do you have any patents, whether plann	ned, pending or issued, bi	oadly relevant to the	work? ☐ Yes ✓ No					

Doyle 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Mr. Doyle reports personal fees and other from Amarin Pharma Inc, outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Doyle 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Granowitz 1



Section 1. Identifying Inform	ation		
1. Given Name (First Name) Craig	2. Surname (Last Name) Granowitz		3. Date 25-September-2018
4. Are you the corresponding author?	Yes ✓ No	Corresponding Autho	or's Name
5. Manuscript Title Cardiovascular Risk Reduction with Icos	apent Ethyl in Hypertrigly	ceridemia	
6. Manuscript Identifying Number (if you kn 18-12792	ow it)		
Section 2. The Work Under Co	onsideration for Public	cation	
Did you or your institution <b>at any time</b> recei any aspect of the submitted work (including statistical analysis, etc.)?			
Are there any relevant conflicts of intere	est? Yes ✓ No		
Section 3. Relevant financial	activities outside the s	submitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep	bed in the instructions. Us	se one line for each en	ntity; add as many lines as you need by
Are there any relevant conflicts of intere			
If yes, please fill out the appropriate info			
Name of Entity	Grant? Personal Nor Fees? S	n-Financial other?	Comments
Amarin Pharma			Amarin Employee - chief medical officer. Also a shareholder of Amarin Pharma
Section 4. Intellectual Proper	ty Patents & Copyri <u>c</u>	jhts	
Do you have any patents, whether plans	ned, pending or issued, br	oadly relevant to the	work? Yes V

Granowitz 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Granowitz reports personal fees and other from Amarin Pharma, outside the submitted work;.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Granowitz 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Idea		••							
lden	tifying Informa	ation							
1. Given Name (First Nam Terry	e)	2. Surnar Jacobsoi	ne (Last Nar n	ne)		3. Date 03-December-2018			
4. Are you the correspond	ling author?	Yes	✓ No	-	Corresponding Author's Name Deepak L. Bhatt, MD MPH				
5. Manuscript Title Cardiovascular Risk Rec	luction with Icosa	pent Ethy	yl in Patien	ts with Elevated	Triglycerio	des			
6. Manuscript Identifying 18-12792	Number (if you kno	w it)							
Section 2. The \	Work Under Co	nsiderat	tion for P	ublication					
any aspect of the submitte statistical analysis, etc.)? Are there any relevant o	ed work (including b conflicts of interes appropriate infor	out not lim	nited to gran Yes nelow. If you	its, data monitorir	ng board, st	ent, commercial, private founda udy design, manuscript prepara ty press the "ADD" button to	ation,		
Name of Institution/Co	mpany	Grant?	Personal Fees?	Non-Financial	Other?	Comments			
Amarin			<b>✓</b>			REDUCE-IT Steering Committe Member	ee		
Section 3. Relev	vant financial a	ctivities	outside	the submitted	l work.				
of compensation) with	entities as describ x. You should repo conflicts of interes	ed in the ort relationst?	instruction onships tha Yes	ns. Use one line t	for each er	cial relationships (regardless ntity; add as many lines as yo e <b>36 months prior to publi</b> o	ou need by		
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
Astra Zeneca			<b>✓</b>			Consultant			
Amgen			<b>✓</b>			Consultant			
Novartis			<b>✓</b>			Consultant			



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments	
Esperion			Consultant	
Regeneron/Sanofi			Consultant	
Section 4				
Section 4. Intellectual Propert	y Patents & Cop	pyrights		
Do you have any patents, whether planne	ed, pending or issue	ed, broadly releva	nt to the work? Yes	✓ No
Section 5. Relationships not co	overed above			
Are there other relationships or activities potentially influencing, what you wrote in Yes, the following relationships/cond.  Yes, the following relationships/conditions/circ.  At the time of manuscript acceptance, journals may ask authors to Section 6.	in the submitted wo ditions/circumstance rcumstances that pre ournals will ask autho disclose further info	rk? es are present (expessent a potential of ors to confirm and	olain below): conflict of interest I, if necessary, update the	
Disclosure Statemen	nt			
Based on the above disclosures, this form below.	૧ will automatically લ્	generate a disclos	sure statement, which wi	ill appear in the box
Dr. Jacobson reports personal fees from fees from Amgen, personal fees from Nothe submitted work.				



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform			
Identifying Inform	nation		
Given Name (First Name)  Terry	2. Surname (Last Name) Jacobson		3. Date 25-September-2018
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Autho	or's Name
5. Manuscript Title Cardiovascular Risk Reduction with Ico	sapent Ethyl in Hypertrigly	vceridemia	
6. Manuscript Identifying Number (if you k	now it)		
Section 2. The Work Under C	onsideration for Publi	cation	
any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, dangers.  Test? Yes No  Tormation below. If you have	ata monitoring board, st	ent, commercial, private foundation, etc.) for udy design, manuscript preparation, ity press the "ADD" button to add a row.
Name of Institution/Company	Grant	n-Financial Other?	Comments
Amarin			REDUCE-IT Steering Committee Member
Section 3. Relevant financial	activities outside the	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as describing the "Add +" box. You should re	ribed in the instructions. U	se one line for each er	
Are there any relevant conflicts of inter If yes, please fill out the appropriate inf			
Name of Entity	Grant	n-Financial Other?	Comments
Astra Zeneca			Consultant
Amgen			Consultant
Novartis			Consultant



Name of Entity	Grant?	Personal   Fees?	Non-Financial Support?	Other?	Comn	nents	
Esperion		<b>✓</b>			Consulta	ant	
Regeneron/Sanofi		<b>✓</b>			Consulta	ant	
Section 4. Intellectual F	Property Pate	nts & Copy	yrights				
Do you have any patents, whether If yes, please fill out the appropri Excess rows can be removed by p	ate information b	elow. If you				✓ Yes  No the "ADD" button to a	dd a row.
Patent?	Pending? Issue	License	d? Royalties?	License	ee?	Comments	
Adherence to Refills and Medications Scale (ARMS)		<b>✓</b>		Emory Tec 18080		Adherence scale designe low literacy patients	d for
Section 5. Relationship	os not covered	above					
Are there other relationships or a potentially influencing, what you	ectivities that reac	lers could pe		influence	d, or tha	t give the appearance	of
Yes, the following relationshi  No other relationships/condi			•			t	
At the time of manuscript accept On occasion, journals may ask au	•						atements.
Section 6. Disclosure St	atement						
Based on the above disclosures, below.	this form will auto	omatically ge	enerate a disclo	sure state	ement, w	hich will appear in the	box
Dr. Jacobson reports personal fe fees from Amgen, personal fees the submitted work; In addition Emory Tech ID 18080.	from Novartis, pe	rsonal fees f	rom Esperion, p	personal f	ees from	Regeneron/Sanofi, o	utside



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Jiao 1



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Lixia	2. Surname (Last Name) Jiao		3. Date 25-September-2018
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Autho Deepak L. Bhatt	r's Name
5. Manuscript Title Cardiovascular Risk Reduction with Icos	apent Ethyl in Hypertrigly	ceridemia	
6. Manuscript Identifying Number (if you kr 18-12792	now it)	_	
Section 2. The Work Under Co	onsideration for Public	cation	
Did you or your institution <b>at any time</b> rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da	. , .	•
Section 3. Relevant financial	activities outside the s	submitted work.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intered If yes, please fill out the appropriate info	bed in the instructions. Us port relationships that werest?	se one line for each en	tity; add as many lines as you need by
Name of Entity	Grant? Personal Fees? S	n-Financial other?	Comments
Amarin Pharma Inc			Employee and stock shareholder of Amarin (sponsor)
Section 4. Intellectual Proper	ty Patents & Copyric	ghts	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the v	work? Yes 🗸 No

Jiao 2



Section 5. Relationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Continue C
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Jiao reports personal fees and other from Amarin Pharma Inc, outside the submitted work; .

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Jiao 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Juliano 1



Section 1. Identifying Inform	ation								
Given Name (First Name) Rebecca	2. Surname (Last Name) Juliano		3. Date 25-September-2018						
4. Are you the corresponding author?	Yes ✓ No	Corresponding Autho	or's Name						
5. Manuscript Title Cardiovascular Risk Reduction with Icosapent Ethyl in Hypertriglyceridemia									
6. Manuscript Identifying Number (if you kn 18-12792	ow it)	_							
Section 2. The Work Under Co	onsideration for Publi	cation							
Did you or your institution <b>at any time</b> receing any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere	but not limited to grants, da								
Section 3. Relevant financial a	activities outside the	submitted work.							
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should repart there any relevant conflicts of interesting the second conflicts of interesting	bed in the instructions. Uport relationships that we st?  Yes Normation below.	se one line for each er re <b>present during the</b>	ntity; add as many lines as you need by						
Name of Entity	Grant? Personal No	n-Financial Support?	Comments						
Amarin Pharma Inc			Employee and stock shareholder of Amarin (sponsor)						
Section 4. Intellectual Proper	ty Patents & Copyri	ghts							
Do you have any patents, whether plann	ned, pending or issued, b	roadly relevant to the	work? ☐ Yes   ✓ No						

Juliano 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Juliano reports personal fees and other from Amarin Pharma Inc, outside the submitted work; .

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Juliano 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

1

Ketchum



Section 1. Identifying Inform	ation								
Given Name (First Name)  Steven	2. Surname (Last Name) Ketchum		3. Date 25-September-2018						
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author Deepak L. Bhatt	or's Name						
5. Manuscript Title Cardiovascular Risk Reduction with Icosapent Ethyl in Hypertriglyceridemia									
6. Manuscript Identifying Number (if you kn 18-12792	ow it)	_							
Section 2. The Work Under Co									
The Work Officer Co	onsideration for Publi								
Did you or your institution <b>at any time</b> recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da								
Section 3. Relevant financial	activities outside the	submitted work.							
Place a check in the appropriate boxes in of compensation) with entities as descriclicking the "Add +" box. You should repare there any relevant conflicts of interesting the second conflicts of the	bed in the instructions. Uport relationships that we start with the start we will be start with the start with	se one line for each er re <b>present during the</b>	ntity; add as many lines as you need by						
Name of Entity	Grant? Personal Fees? S	n-Financial other?	Comments						
Amarin Pharma, Inc. (Amarin)			Employee and stock shareholder of Amarin (sponsor)						
Section 4. Intellectual Proper	ty Patents & Copyri	ghts							
Do you have any patents, whether plann	ned, pending or issued, bi	roadly relevant to the	work? ☐ Yes ✓ No						

Ketchum 2



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Ketchum reports personal fees and other from Amarin Pharma, Inc. (Amarin), outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Ketchum 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



	ı						
Section 1.	ldentifying Inforn	nation					
1. Given Name (Fi Michael	rst Name)	2. Surname Miller	(Last Name	e)		3. Date 29-November-2018	
4. Are you the cor	responding author?	Yes	Yes No Corresponding Author's Name Deepak L. Bhatt, MD MPH				
5. Manuscript Title Cardiovascular F	e lisk Reduction with Ico	sapent Ethyl i	n Patients	s with Elevated T	riglyceri	des	
6. Manuscript Ide 18-12792.R2	ntifying Number (if you kı	now it)					
Section 2.	The Work Under C	onsideratio	n for Pu	blication			
	ubmitted work (including					ent, commercial, private foundation, etc.) for udy design, manuscript preparation,	
	evant conflicts of inter	est? 🗸 Yes	. N	lo			
	out the appropriate info be removed by pressin			have more than	one enti	ty press the "ADD" button to add a row.	
				Non-Financial	7		
Name of Institut	tion/Company	Grant	Fees?	Support?	Other •	Comments	
Amarin			<b>✓</b>			Consulting fees	
Akcea			<b>✓</b>			Consulting fees	
Section 3.	Relevant financial	activities o	utside tl	ne submitted	work.		
of compensation	n) with entities as descr	ibed in the in	structions	s. Use one line fo	or each er	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.	
	evant conflicts of inter			o			
If yes, please fill o	out the appropriate inf	ormation belo	ow.				
Name of Entity		Grant•	ersonal Fees	Non-Financial Support?	Other?	Comments	
Amarin			<b>✓</b>			Consulting fees	
Akcea			<b>✓</b>			Consulting fees	



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Miller reports personal fees from Amarin, personal fees from Akcea, during the conduct of the study; personal fees from Amarin, personal fees from Akcea, outside the submitted work.

#### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	ation		
1. Given Name (Fi Michael	rst Name)	2. Surname (Last Nam Miller	e)	3. Date 25-September-2018
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Au Deepak L. Bhatt	
5. Manuscript Title Cardiovascular R	e isk Reduction with Icos	apent Ethyl in Hypertı	riglyceridemia	
6. Manuscript Ider 18-12792	ntifying Number (if you kn	now it)		
	l			
Section 2.	The Work Under Co	onsideration for Pu	blication	
any aspect of the s statistical analysis, Are there any rel If yes, please fill o	ubmitted work (including etc.)? evant conflicts of intere	but not limited to grantest? Yes Normation below. If you	s, data monitoring board	nment, commercial, private foundation, etc.) for d, study design, manuscript preparation, entity press the "ADD" button to add a row.
Name of Institut	ion/Company	Grant? Personal Fees?	Non-Financial Othe	Comments
Amarin				Steering Committee Member
Section 3.	Relevant financial	activities outside t	he submitted work	
of compensation clicking the "Add Are there any rel	) with entities as descri	bed in the instruction port relationships that	s. Use one line for each were <b>present during</b>	ancial relationships (regardless of amount n entity; add as many lines as you need by the 36 months prior to publication.
Section 4.	Intellectual Proper	ty Patents & Cop	yrights	
Do you have any	patents, whether plans	ned, pending or issued	d, broadly relevant to t	the work? ☐ Yes ✓ No



Section 5. Polationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Miller reports personal fees from Amarin, during the conduct of the study; .

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Information	ation -				
Given Name (First Name)     Philippe Gabriel	2. Surna	me (Last Nar	ne)		3. Date 25-September-2018
4. Are you the corresponding author?	Yes	<b>√</b> No	Correspond Deepak L	_	or's Name
5. Manuscript Title Cardiovascular Risk Reduction with Icosa	pent Eth	yl in Hyper	triglyceridemia		
6. Manuscript Identifying Number (if you known 18-12792	ow it)				
Section 2. The Work Under Co	nsidera	tion for P	ublication		
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of interesting the properties of t	but not linst? ✓ rmation k	nited to gran Yes pelow. If yo	nts, data monitoring	g board, st	udy design, manuscript preparation,
Excess rows can be removed by pressing		1	New Finencial		
Name of Institution/Company	Grant •	Personal Fees?	Non-Financial Support?	Other?	Comments
Amarin		<b>✓</b>			Executive Steering Committee membership, consulting
Section 3. Relevant financial a	ctivitie	s outside	the submitted	work.	
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should rep	oed in the	instruction	ns. Use one line fo	or each er	ntity; add as many lines as you need by
Are there any relevant conflicts of intere			No		
If yes, please fill out the appropriate info	rrnation k	pelow.			
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Bayer/Janssen	<b>✓</b>	<b>✓</b>			Steering Committee for trials, grant for epidemiological studies
Merck	<b>√</b>	<b>√</b>			Speaker fees, grant for epidemiological studies



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments		
Sanofi	<b>✓</b>	<b>✓</b>			co-chair of the ODYSSEY outcomes trial. Co-chair of the SCORED trial . Consulting, Speaking.		
Amgen		<b>✓</b>			consulting and speaking		
Bristol Myers Squibb		<b>✓</b>			consulting and speaking, Critical event committee work		
Boehringer-Ingelheim		<b>✓</b>			Executive steering committee REDUAL PCI trial		
Pfizer		<b>✓</b>			Critical event committee work		
Novartis		<b>✓</b>			Executive steering committee PARADISE MI trial, consulting		
Regeneron		<b>✓</b>			consulting		
Lilly		<b>✓</b>			consulting		
AstraZeneca		<b>✓</b>			cochair THEMIS trial, consulting		
Servier	<b>√</b>	<b>✓</b>			Personal fees as Chair of the Data Monitoring Committee for the ATPCI trial and as Chair of the CLARIFY registry. Grant for analyses of the CLARIFY registry		
Section 4.  Intellectual Property Patents & Copyrights  Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo							
Section 5. Relationships not o	overed	above					
Are there other relationships or activities potentially influencing, what you wrote it				nfluence	d, or that give the appearance of		
Yes, the following relationships/conditions/cir							
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					• •	ents.	



#### Section 6.

#### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. STEG reports personal fees from Amarin, during the conduct of the study; grants and personal fees from Bayer/Janssen, grants and personal fees from Merck, grants and personal fees from Sanofi, personal fees from Amgen, personal fees from Bristol Myers Squibb, personal fees from Boehringer-Ingelheim, personal fees from Pfizer, personal fees from Novartis, personal fees from Regeneron, personal fees from Lilly, personal fees from AstraZeneca, grants and personal fees from Servier, outside the submitted work;

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Informa	ation					
	identifying illioning	ation					
1. Given Name (Fi	rst Name)		e (Last Name	5)		3. Date	
Jean-Claude		Tardif				25-September-2018	
4 Are you the cor	responding author?	Yes	✓ No	Correspond	dina Autha	or's Name	
i. The you the con	esponding dutilor.		V	Deepak L.	_	or a realife	
5. Manuscript Title							
	: isk Reduction with Icosa	pent Ethyl	in Hypertri	glyceridemia			
<ol><li>6. Manuscript Ider 18-12972</li></ol>	ntifying Number (if you kno	ow it)					
10 12372							
Section 2.							ı
Section 2.	The Work Under Co	nsiderati	on for Pul	blication			
						ent, commercial, private foundation, et	c.) for
any aspect of the s statistical analysis,		but not limi	ted to grants	i, data monitoring	g board, st	udy design, manuscript preparation,	
	evant conflicts of interes	st? ✓ Ye	es No	0			
				have more thar	one enti	ity press the "ADD" button to add a	row.
Excess rows can l	oe removed by pressing	the "X" bu	tton.				
Name of Institut	ion/Company	Grant?	Personal   1	Non-Financial	Other?	Comments	
	,		Fees?	Support?			
Amarin		<b>✓</b>	<b>✓</b>			Honorarium as study executive	
		V	•			committee member	
Section 3.	Relevant financial a	ctivities	outside th	e submitted	work		
_	neievant iniancial a	ictivities	butsiae tii	ic subilifica	work.		
						cial relationships (regardless of amo	
						ntity; add as many lines as you need e <b>36 months prior to publication</b> .	by
_	evant conflicts of interes				uning th	e 30 months prior to publication.	
•	out the appropriate info						
ii yes, pieuse iiii e	at the appropriate info	ination be	1011.				
Name of Entity		Grant?	Personal I	Non-Financial	Other?	Comments	
- Name of Entity		Grant	Fees?	Support?	Otner•	Comments	
AstraZeneca		<b>✓</b>					
DalCor		✓	✓		✓	Minor equity interest; consulting fee	
			<b>V</b>		<b>V</b>		
Esperion		✓					



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments			
lonis	<b>✓</b>							
Pfizer	<b>✓</b>	<b>✓</b>			Honorarium as study executive committee co-chairman			
Sanofi	<b>✓</b>	<b>✓</b>			Honorarium as study executive committee member			
Servier	✓	<b>✓</b>			Consulting fee			
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.								
Patent?	Pending?	ed? Licens	ed?Royalties?	License	ce? Comments			
Dalcetrapib for Therapeutic Use (U.S. 9,909,178 B2)					Patent granted March 6, 2018.			
Section 5.  Relationships not covered above								
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?								
Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest								
At the time of manuscript accepta On occasion, journals may ask aut					sary, update their disclosure stateme elationships.	ents.		

#### Section 6.

#### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Tardif reports grants and personal fees from Amarin, during the conduct of the study; grants from AstraZeneca, grants, personal fees and other from DalCor, grants from Esperion, grants from Ionis, grants and personal fees from Pfizer, grants and personal fees from Sanofi, grants and personal fees from Servier, outside the submitted work; In addition, Dr. Tardif has a patent Dalcetrapib for Therapeutic Use (U.S. 9,909,178 B2) issued.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.